Your search for non small cell lung cancer returned 449 results

Daiichi Sankyo and ArQule announced that the first patient has been enrolled in the Phase 3 trial of ARQ 197 in combination with erlotinib, for patients diagnosed with non-squamous, non-small cell lung cancer (NSCLC) who have received one or two prior systemic anti-cancer therapies.

Alder Biopharmaceuticals announced that patients with late-stage non-small cell lung cancer (NSCLC) showed improvement in cancer-related anemia and symptoms of the disease in a Phase 2a clinical trial of ALD518.

ArQule and Daiichi Sankyo announced the presentation of data from a Phase 2 trial showing encouraging overall survival (OS) results with ARQ 197 in combination with erlotinib among patients with advanced, refractory non-small cell lung cancer (NSCLC).

Sugemalimab improved progression-free survival whether patients received sequential or concurrent chemoradiotherapy.

There was no improvement in overall survival with bevacizumab.

There was an improvement in progression-free survival despite crossover.

The Food and Drug Administration has granted accelerated approval to Tabrecta™ (capmatinib; Novartis).

The approval of Imfinzi is based on the positive PFS data from the Phase 3 PACIFIC trial.

Genentech announced that the Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumor has EGFR or ALK gene abnormalities.

Chemotherapeutic and biologic agents for the treatment of non-small cell lung cancer (NSCLC).